CLSI VET01S™
Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

CLSI VET01S includes updated tables for the Clinical and Laboratory Standards Institute veterinary antimicrobial susceptibility testing standard VET01.

A CLSI supplement for global application.
Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

Dubraska V. Diaz-Campos, DVM, PhD
Brian V. Lubbers, DVM, PhD, DACVCP
Stefan Schwarz, DVM
Robert Bowden, BS
Claire R. Burbick, DVM, PhD, DACVM
Merran Govendir, PhD, BVSc, FHERDSA, MANZCVSc
Scott B. Killian, BS
Sara D. Lawhon, DVM, PhD, DACVM
Xian-Zhi Li, PhD
Kelli Maddock, MS, MLS(ASCP)M
Ron A. Miller, PhD, MS
Ian Morrissey, BSc, MBA, PhD, FRSM
K. Marcia Murphy, DVM, DACV
Mark G. Papich, DVM, MS
Michael T. Sweeney, MS
Ronald Tessman, DVM, PhD, DACVIM, DACVPM
S. Steve Yan, PhD

Abstract

The data in the tables are valid only if the methodologies in CLSI VET01 are followed. CLSI VET01 contains information about disk and dilution susceptibility test procedures for aerobic and facultatively anaerobic bacteria. Clinicians need information from the microbiology laboratory for treating and/or confirming treatment decisions for their patients with bacterial infections and depend heavily on this information for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to interpret results based on the most current breakpoints and interpretive categories for antimicrobial agents used in veterinary medicine.

The tables presented in CLSI VET01S represent the most current information for drug selection, interpretation, and QC using the procedures standardized in CLSI VET01. Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in black boldface type.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100  F: +1.610.688.0700  E: customerservice@clsi.org  W: www.clsi.org
# Contents

Abstract ............................................................................................................. i

Committee Membership .................................................................................... iii

Overview of Changes ........................................................................................ viii

Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges ... xix

CLSI Reference Methods vs Commercial Methods and CLSI vs Regulatory Authority Breakpoints ........................................................................................................ xx

CLSI Veterinary-Specific Breakpoint Additions and Revisions Since the Previous Edition ........................................................................................................ xxi

CLSI Subcommittee on Veterinary Antimicrobial Susceptibility Testing Mission Statement and Responsibilities .................................................................................. xxiii

Instructions for Use of Tables ............................................................................. 1

References ........................................................................................................ 17

Table 1. Antimicrobial Agents That Could Be Considered for Routine Testing by Veterinary Microbiology Laboratories .......................................................... 18

Table 2A. Zone Diameter and MIC Breakpoints for Enterobacterales ................ 24

Table 2B. Zone Diameter and MIC Breakpoints for *Pseudomonas aeruginosa* .......... 42

Table 2C-1. Zone Diameter and MIC Breakpoints for *Staphylococcus* spp. for β-Lactams and β-Lactam Combination Agents ..................................................... 48

Table 2C-2. Zone Diameter and MIC Breakpoints for *Staphylococcus* spp. for Non-β-Lactams ................................................................................................. 58

Table 2D. Zone Diameter and MIC Breakpoints for *Enterococcus* spp. ................ 70

Table 2E. Zone Diameter and MIC Breakpoints for *Streptococcus* spp. .............. 78

Table 2F. Zone Diameter and MIC Breakpoints for *Bordetella bronchiseptica* .......... 92

Table 2G. Zone Diameter and MIC Breakpoints for *Mannheimia haemolytica* ........ 94

Table 2H. Zone Diameter and MIC Breakpoints for *Pasteurella multocida* .......... 96

Table 2I. Zone Diameter and MIC Breakpoints for *Actinobacillus* spp. ............ 100

Table 2J. Zone Diameter and MIC Breakpoints for *Histophilus somni* ............. 104
Contents (Continued)

Table 2K. Zone Diameter and MIC Mastitis (Intramammary Infection) Breakpoints for Enterobacterales ................................................................. 106
Table 2L. Zone Diameter and MIC Mastitis (Intramammary Infection) Breakpoints for *Staphylococcus* spp. ................................................................. 110
Table 2M. Zone Diameter and MIC Mastitis (Intramammary Infection) Breakpoints for *Streptococcus* spp. ................................................................. 120
Table 3. QC Strain Culture Collection Numbers for Antimicrobial Susceptibility Tests ................................................................. 122
Table 4A. Zone Diameter QC Ranges for Nonfastidious Organisms ......................................................................................................................... 124
Table 4B. Zone Diameter QC Ranges for Fastidious Organisms ................................................................................................................................. 128
Table 4C. Zone Diameter QC Ranges for *Campylobacter jejuni* ATCC® 33560 ........................................................................................................ 130
Table 4D. Disk Diffusion Reference Guide to QC Frequency ................................................................................................................................. 132
Table 4E. Disk Diffusion Troubleshooting Guide ................................................................................................................................. 134
Table 5A. MIC QC Ranges for Nonfastidious Organisms ................................................................. 138
Table 5B. MIC QC Ranges for Fastidious Organisms (Broth Dilution Methods) ................................................................. 140
Table 5C. MIC QC Ranges for *Campylobacter jejuni* ATCC® 33560 ........................................................................................................ 142
Table 5D. MIC QC Ranges for Anaerobes (Agar Dilution Method) ................................................................................................................................. 144
Table 5E. MIC QC Ranges for Anaerobes (Broth Microdilution Method) ................................................................................................................................. 146
Table 5F. MIC Reference Guide to QC Frequency ................................................................................................................................. 148
Table 5G. MIC Troubleshooting Guide ................................................................................................................................. 150
Table 6. Solvents and Diluents for Preparing Stock Solutions of Antimicrobial Agents .... 156
Table 7A. Tests for Extended-Spectrum β-Lactamases in *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Escherichia coli*, and *Proteus mirabilis* ................................................................................................................................. 158
Introduction to Tables 7B and 7C. Tests for Carbapenemases in Enterobacterales and *Pseudomonas aeruginosa* ................................................................................................................................. 164
Table 7B. Carba NP Test for Suspected Carbapenemase Production in Enterobacterales and *Pseudomonas aeruginosa* ................................................................................................................................. 166
Table 7C. Modified Carbapenem Inactivation Methods for Suspected Carbapenemase Production in Enterobacterales and *Pseudomonas aeruginosa* ................................................................................................................................. 174
Contents (Continued)

Table 7D. Tests for Detecting β-Lactamase Production in *Staphylococcus* spp. .......... 186

Table 7E. Disk Diffusion Test for Prediction of *mecA*-Mediated Resistance in *Staphylococcus* spp. ................................................................. 190

Table 7F. Vancomycin Agar Screen for *Staphylococcus aureus* and *Enterococcus* spp. .................................................................................. 192

Table 7G. Tests for Detecting Inducible Clindamycin Resistance in *Staphylococcus* spp., *Streptococcus* spp. β-Hemolytic Group, and *Streptococcus pneumoniae* .................... 194

Table 7H. Tests for Detecting High-Level Aminoglycoside Resistance in *Enterococcus* spp. (Includes Disk Diffusion) ............................................................ 196

Appendix A. Suggestions for Confirming Resistant, Intermediate, or Nonsusceptible Antimicrobial Susceptibility Test Results and Organism Identification ....................... 198

Appendix B. Intrinsic Resistance ........................................................................... 204

Appendix C. QC Strains for Antimicrobial Susceptibility Tests .............................. 214

Appendix D. Sources of Antimicrobial Agent Disks ............................................. 218

Appendix E. Dosage Regimens Used to Establish Susceptible or Susceptible-Dose Dependent Veterinary-Specific Breakpoints ................................................................. 220

Appendix F. Susceptible-Dose Dependent Interpretive Category ............................ 232

Appendix G. Epidemiological Cutoff Values .......................................................... 238

Appendix H. CLSI Veterinary-Specific Breakpoint Additions/Revisions to CLSI VET01 Supplements Since 1999 ................................................................. 242

Glossary I. Antimicrobial Class and Subclass Designations, Antimicrobial Agents, and Antimicrobial Resistance Mechanisms .......................................................... 252

Glossary II. Abbreviations Commonly Used for Antimicrobial Agents Incorporated Into Disks or Susceptibility Panels ................................................................. 256

Glossary III. List of Identical Abbreviations Used for More Than One Antimicrobial Agent in US Diagnostic Products ................................................................. 258

The Quality Management System Approach .......................................................... 260
Instructions for Use of Tables

These instructions apply to:

- **Table 1**: suggested groupings of antimicrobial agents that could be considered for routine testing and reporting by microbiology laboratories. Placement of antimicrobial agents in Table 1 is either based on approval by relevant regulatory organizations or on use consistent with good clinical practice.

- **Tables 2A through 2M**: tables for each organism group that contain:
  - Recommended testing conditions
  - Routine QC recommendations (also see Chapter 8 in CLSI VET011)
  - General comments for testing the organism group and specific comments for testing agent-organism combinations
  - Suggested agents that could be considered for routine testing and reporting by veterinary microbiology laboratories, as specified in Table 1 (test/report groups A, B, C, D, E)
  - Zone diameter and minimal inhibitory concentration (MIC) breakpoints

- **Tables 3 through 5**: tables for acceptable QC organisms, sources, and acceptable result ranges

- **Table 6**: table of solvents and diluents for preparing stock solutions of antimicrobial agents

- **Tables 7A through 7H**: tables describing tests to detect resistance types in specific organisms or organism groups (also see Chapter 7 in CLSI VET011)

---

I. Selecting Antimicrobial Agents for Testing and Reporting

A. Appropriate Agents for Routine Testing

Selecting the most appropriate antimicrobial agents to test and report is a decision best made by each laboratory in consultation with veterinarians, infectious diseases practitioners, clinical microbiologists, clinical pharmacologists, and antimicrobial stewardship teams, if available. The recommendations for each organism group include antimicrobial agents that show acceptable *in vitro* test performance. Considerations in the assignment of antimicrobial agents to specific test/report groups include clinical efficacy, prevalence of resistance, minimizing emergence of resistance, cost, regulatory agency-approved clinical indications for use, and current consensus recommendations for first-choice and alternative agents. Tests of selected agents may be useful for infection control and/or monitoring purposes.

B. Equivalent Agents

Antimicrobial agents listed together in a single box are agents for which interpretive categories (susceptible, susceptible-dose dependent, intermediate, or resistant) and clinical efficacy are similar. Within each box, an “or” is used between agents,
as needed, to indicate agents for which cross-resistance and cross-susceptibility are nearly complete. Results from one agent connected by an “or” can be used to predict results for the other agent. For an example, see human breakpoints for azithromycin or clarithromycin, or erythromycin against staphylococci in Table 2C-2. The results obtained from testing ampicillin could be reported along with a comment that the isolate is also susceptible to amoxicillin. For drugs connected with an “or,” combined major and very major errors are fewer than 3%, and minor errors are fewer than 10%, based on a large population of bacteria tested (see CLSI VET02© and CLSI M23© for description of error types). When no “or” connects agents within a box, testing of one agent cannot be used to predict results for another, owing either to discrepancies or insufficient data.

C. Test/Report Groups

The antimicrobial agents listed in groups A, B, C, D, and E in Table 1 include recommendations for appropriate reporting. Some or all antimicrobial agents listed in groups A, B, C, and D in Table 1 have been approved by the applicable regulatory agencies or authorities for treatment of diseases in the indicated host animal. Group A and B designations are also stated in the Table 2 series, which lists the breakpoints and interpretive categories for species-specific breakpoints in each organism group. To avoid misinterpretation, routine reports to veterinarians should include antimicrobial agents appropriate for therapeutic use.

- **Group A** includes antimicrobial agents with veterinary-specific breakpoints and interpretive categories that are considered appropriate for inclusion in a routine, primary testing panel for food and companion animals, as well as for routine reporting of results for the specified organism groups. The recommended hierarchy for reporting is to first report group A agents over those using human breakpoints, because these compounds have demonstrated an acceptable level of correlation between in vitro susceptibility test results and clinical outcome.

- **Group B** includes antimicrobial agents with veterinary-specific breakpoints and interpretive categories that are considered appropriate for testing and selective reporting. Antimicrobial agents listed in group B are considered secondary choices by the CLSI Subcommittee on Veterinary Antimicrobial Susceptibility Testing to be considered for use only when resistance is detected for agents in group A or when there are no other reasonable alternatives. Testing may be conducted routinely as part of an antimicrobial resistance (AMR) surveillance program; however, reporting should be done cautiously and with guidance from an antimicrobial stewardship program, if available.

- **Group C** includes antimicrobial agents that use human breakpoints and interpretive categories and are next in the hierarchy to report. These agents may perform adequately, but outcome for many veterinary applications has not been demonstrated. The veterinary laboratory may use its discretion to decide whether to selectively report the results from testing these agents.

- **Group D** includes antimicrobial agents that are regulatory agency-approved for use in the specific animal species. Although QC data are available for these agents, they do not have veterinary- or human-specific CLSI-approved
Appendix B. (Continued)


<table>
<thead>
<tr>
<th>Organism</th>
<th>Cephalosporins</th>
<th>Vancomycin</th>
<th>Aminoglycosides</th>
<th>Clindamycin</th>
<th>Trimethoprim</th>
<th>Trimethoprim-sulfamethoxazole</th>
<th>Fusidic Acid</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Enterococcus faecalis</em></td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R</td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td>R</td>
</tr>
<tr>
<td><em>Enterococcus faecium</em></td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R</td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td>R</td>
</tr>
<tr>
<td><em>Enterococcus gallinarum</em></td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R</td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R</td>
<td></td>
<td>R</td>
</tr>
</tbody>
</table>

Abbreviation: R, resistant.

Footnote

a. **Warning**: For *Enterococcus* spp., aminoglycosides (except for high-level resistance testing), cephalosporins, clindamycin, and trimethoprim-sulfamethoxazole may appear active *in vitro* but are not effective clinically and should not be reported as susceptible.

**NOTE**: These gram-positive bacteria are also intrinsically resistant to aztreonam, nalidixic acid, and polymyxins (including colistin).

B5. Other Gram-Positive Bacteria of Importance in Veterinary Medicine

<table>
<thead>
<tr>
<th>Organism</th>
<th>Penicillin</th>
<th>Cephalosporins (including ceftazidime)</th>
<th>Vancomycin</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Bacillus cereus</em>&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Erysipelothrix rhusiopathiae</em></td>
<td></td>
<td></td>
<td>R</td>
</tr>
<tr>
<td><em>Lactobacillus</em> spp. (some species)</td>
<td></td>
<td></td>
<td>R</td>
</tr>
<tr>
<td><em>Listeria monocytogenes</em></td>
<td></td>
<td></td>
<td>R</td>
</tr>
</tbody>
</table>

Abbreviation: R, resistant.

Footnote

a. *B. cereus* may be resistant to other β-lactam agents due to chromosomally encoded β-lactamases.

**NOTE**: These gram-positive bacteria are also intrinsically resistant to aztreonam, nalidixic acid, and polymyxins (including colistin).